8 D), indicating that the findings for the IAP antagonist depicted inFigs

8 D), indicating that the findings for the IAP antagonist depicted inFigs. of cellular FLICE-inhibitory protein (cFLIP). However, only cFLIPLand not cFLIPSinterfered with RIP1 recruitment to the DISC and complex II and protected cells from death. These results demonstrate a fundamental role for RIP1 in CD95 signaling and provide support for a physiological role of caspase-independent death receptormediated cell death. == Introduction == The initiators of the extrinsic cell death pathway are a subclass of TNF superfamily (TNFSF) receptors called death receptors (DRs). A common feature of DR signaling is the formation of a primary plasma membraneassociated death-inducing signaling complex (DISC) and a secondary independent signaling platform in the cytoplasm (complex II). Complex II GPI-1046 was first demonstrated for TNF-R1 (Micheau and Tschopp, 2003) but subsequently was also shown for other DR GPI-1046 pathways (Varfolomeev et al., 2005;Lavrik et al., 2008). However, the mechanisms leading to the formation of these secondary complexes and their significance to signaling outcome are still unknown. DR signaling pathways are controlled by inhibitors such as cellular FLICE-inhibitory protein (FLIP [cFLIP]) or X-linked inhibitor of apoptosis (IAP [XIAP]; for review seeMeier and Vousden, 2007). ThecFLIPgene can give rise to 11 distinct isoforms, but in most cells, a long (cFLIPL) and a short isoform (cFLIPS) are the only ones readily detected (for reviews seeKataoka, 2005;Budd et al., 2006). cFLIPLhas a caspase-like domain lacking the critical GPI-1046 catalytic residues present in caspase-8 in addition to two death effector domains, whereas cFLIPScontains only two death effector domains and is structurally related to viral FLIP (vFLIP;Thurau et al., 2006). cFLIP isoforms interact with FADD (Fas-associated protein with death domain [DD]) and caspase-8, are recruited to the DISC, and interfere with caspase activation within this signaling platform (Lavrik et al., 2005;Falschlehner et al., 2007). DRs can also cause nonapoptotic, caspase-independent cell death and elicit nonapoptotic responses (for reviews seeWajant et al., 2003;Kroemer et al., 2009). The significance of these caspase-independent DR pathways is debated, and there is a need to provide additional examples in more physiological scenarios. RIP1 (receptor-interacting protein 1) belongs to the RIP kinase family but is the only family member with a C-terminal DD (Stanger et al., 1995; for review seeFestjens et al., 2007). RIP1 knockout mice are born but die rapidly because of an increased sensitivity to TNF (Kelliher et al., 1998). RIP1, and specifically its DD, was reported to be critical for CD95-mediated necrosis independent of NF-Binducing activity or RIP1 kinase (RIP1K) activity (Holler et al., 2000;Degterev et al., 2005). The development of specific RIP1K inhibitors has facilitated experiments examining the functional role of RIP1K Rabbit polyclonal to AP4E1 in necrosis (Degterev et al., 2008), but the precise role or potential targets of the kinase activity of RIP1 are unknown (Hitomi et al., 2008). A major goal of tumor therapies such as DR agonists is to overcome transformation-induced apoptosis resistance (Hanahan and Weinberg, 2000;Ashkenazi, 2008). However, unfortunately, resistant tumor cells are frequently selected during treatment, exemplifying the need GPI-1046 for novel treatments that can further sensitize tumors GPI-1046 to DR-mediated apoptosis. IAP antagonists are synthetic compounds that were modeled on the N-terminal IAP-binding motif of the mitochondrial protein Smac/DIABLO (Wright and Duckett, 2005). The XIAP-interfering function of Smac-mimetic compounds (IAP antagonists) is crucial for therapeutic efficiency of TNF-related apoptosis-inducing ligand (TRAIL) in xenograft tumor models (Vogler et al., 2008). Recently, it has become apparent that compounds principally designed to target XIAP also target cIAPs by rapid autoubiquitylation and proteasomal degradation of cIAP1 and -2 (Gaither et al., 2007;Petersen et al., 2007;Varfolomeev et al., 2007;Vince et al., 2007;Bertrand et al., 2008). Previous studies have shown that cIAPs can inhibit CD95- and TRAIL-Rinduced apoptosis (McEleny et al., 2004;Wang et al., 2005). It is unlikely that their role will be as direct caspase inhibitors because cIAPs are rather poor inhibitors of caspase activity (Eckelman and Salvesen, 2006). Because cIAPs regulate RIP1 in TNF-R1 and RIP1 plays a role in CD95 signaling, we have investigated the mechanism of DR cell death in the context of IAP inhibition. We show.